Literature DB >> 23414477

Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.

Mauro Borzio1, Fabio Fornari, Ilario De Sio, Angelo Andriulli, Fulvia Terracciano, Giancarlo Parisi, Gianpiero Francica, Mario Salvagnini, Massimo Marignani, Andrea Salmi, Fabio Farinati, Alessandra Carella, Claudia Pedicino, Elena Dionigi, Libera Fanigliulo, Massimo Cazzaniga, Barbara Ginanni, Rodolfo Sacco.   

Abstract

AIM: Adherence to and the applicability of practice guidelines for the management of hepatocellular carcinoma (HCC) in field practice have not been fully addressed. We designed a multicenter field practice prospective study to evaluate the adherence to the 2005 American Association for the Study of Liver Diseases guidelines in Italy. MATERIALS &
METHODS: The study began in September 2008 and consecutively enrolled cirrhotic patients with newly diagnosed HCC from 30 local, nonreference centers in Italy. Patients were stratified according to Child-Pugh, the model for end-stage liver disease, tumor-node metastasis, performance status and the Barcelona Clinic Liver Cancer (BCLC) classifications. The diagnostic and therapeutic strategies adopted in each individual patient were recorded. Statistical analysis was carried out on 536 patients using all of the valuable data.
RESULTS: A total of 286 (54.5%) patients were ≥70 years old. Comorbidities, recorded in 397 (74%) patients, were classified as moderate to severe in 170 patients (43%). Overall, 174 (59%) patients with early-stage BCLC were ≥70 years; 104 (35%) of these had moderate-to-severe comorbidities and 54% were under a regular US surveillance program. Diagnosis was performed by computed tomography in 93% of patients, contrast-enhanced ultrasound in 62% and MRI in 17%. In patients with nodules of ≤2 cm, adherence to noninvasive diagnostic criteria was 56%. Adherence to the BCLC classification was shown to be suboptimal overall, particularly regarding allocation to surgical procedures, and a total of 119 patients (40%) with BCLC stage A did not receive curative therapies.
CONCLUSIONS: This multicenter survey showed that, in the 'real world', adherence to the both the diagnostic and therapeutic American Association for the Study of Liver Diseases 2005 algorithms was low, particularly in patients with early-stage HCC. Difficulties in applying the algorithms in routine clinical practice and the high prevalence of older patients with relevant comorbidities may account for our findings. Strategies to help improve adherence to international guidelines for HCC in field practice are required.

Entities:  

Mesh:

Year:  2013        PMID: 23414477     DOI: 10.2217/fon.12.183

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  12 in total

1.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival.

Authors:  Manuel Hernández-Guerra; Alejandro Hernández-Camba; Juan Turnes; Luis Martin Ramos; Laura Arranz; José Mera; Javier Crespo; Enrique Quintero
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

Review 3.  Management of hepatocellular carcinoma in the elderly.

Authors:  Mauro Borzio; Elena Dionigi; Giancarlo Parisi; Ivana Raguzzi; Rodolfo Sacco
Journal:  World J Hepatol       Date:  2015-06-18

Review 4.  Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma.

Authors:  Francesco Tovoli; Giulia Negrini; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2016-03-23

5.  Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage.

Authors:  Luciana Kikuchi; Aline Lopes Chagas; Regiane S S M Alencar; Claudia Tani; Marcio A Diniz; Luiz A C D'Albuquerque; Flair José Carrilho
Journal:  Clinics (Sao Paulo)       Date:  2017-08       Impact factor: 2.365

6.  Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.

Authors:  Zhi-Huan Lin; Xing Li; Ying-Fen Hong; Xiao-Kun Ma; Dong-Hao Wu; MingSheng Huang; Zhan-Hong Chen; Jie Chen; Min Dong; Li Wei; Tian-Tian Wang; Dan-Yun Ruan; Ze-Xiao Lin; Xiang Zhong; Yan-Fang Xing; Jing-Yun Wen; Xiang-Yuan Wu; Qu Lin
Journal:  Tumour Biol       Date:  2015-09-28

Review 7.  Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Renumathy Dhanasekaran; Jayant A Talwalkar
Journal:  Curr Gastroenterol Rep       Date:  2015-09

Review 8.  Advances in Local and Systemic Therapies for Hepatocellular Cancer.

Authors:  Ali A Mokdad; Amit G Singal; Adam C Yopp
Journal:  Curr Oncol Rep       Date:  2016-02       Impact factor: 5.075

9.  Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma.

Authors:  Francesca Romana Ponziani; Irene Spinelli; Emanuele Rinninella; Lucia Cerrito; Antonio Saviano; Alfonso Wolfango Avolio; Michele Basso; Luca Miele; Laura Riccardi; Maria Assunta Zocco; Brigida Eleonora Annicchiarico; Matteo Garcovich; Marco Biolato; Giuseppe Marrone; Anna Maria De Gaetano; Roberto Iezzi; Felice Giuliante; Fabio Maria Vecchio; Salvatore Agnes; Giovanni Addolorato; Massimo Siciliano; Gian Lodovico Rapaccini; Antonio Grieco; Antonio Gasbarrini; Maurizio Pompili
Journal:  World J Hepatol       Date:  2017-12-28

10.  Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias.

Authors:  Yi-Hao Yen; Yu-Fan Cheng; Jing-Houng Wang; Chih-Che Lin; Chien-Hung Chen; Chih-Chi Wang
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.